Addressing the Mechanism of Action for the AKT Pathway in TNBC
Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Rebecca Dent, MD, a senior consultant and head of Medical Oncology Department at the National Cancer Centre Singapore, discusses how investigators are targeting pathways in patients with triple negative breast cancer (TNBC).
Dent says that physicians in this setting having been trying to target the AKT pathway considering how important it is in carcinogenesis. PI3K and mTOR inhibition have been looked at previously, but she believes the importance of AKT inhibitors have been underappreciated, especially in the TNBC space.
Up to 40% of patients with TNBC have loss-of-function negative regulator and gain-of-function positive regulator aberrations in the AKT pathway, according to Dent. Some things can things can up-regulate AKT in a patient beyond their mutational status, such as the impact of chemotherapy. Preclinical data looking at cell lines in these patients showed that when investigators added AKT inhibitors for taxane-based chemotherapy, the benefits were not just additive, but synergistic, she thinks. This data was the basis for the randomized phase 2 LOTUS trial (NCT02162719) of paclitaxel versus ipatasertib (RG7440) in patients with metastatic TNBC.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
